Risk factors for recurrence of small hepatocellular carcinoma after long-term follow-up of percutaneous radiofrequency ablation.
|
| Abstract |
Radiofrequency ablation (RFA) as a local therapy for liver cancer is widely used. The study is to evaluate the therapeutic efficacy of RFA on hepatocellular carcinoma (HCC) and identify the risk factors for recurrence. Clinical records of 124 patients with 135 small HCC with percutaneous RFA as a first-line treatment modality were evaluated in Liver Cancer Institute, Zhongshan Hospital from October 2001 to December 2006. With a median follow-up period of 46 months after RFA therapy, the 1-, 2-, 3-, 4-, and 5-year cumulative survival rates and disease-free survival rates were 91, 70, 61, 48 and 40% and 64, 44, 31, 24 and 24%, respectively. The total recurrence and metastasis rates were 50 and 6.5%, respectively. Independent risk factors for recurrence after RFA included tumor with diameter more than 3 cm, located near the intrahepatic blood vessels, subcapsular locations and PT prolonged more than 3s. Severe complications occurred in 2 cases (1.6%), including biliary tract hemorrhage and subphrenic effusion. RFA appears to be a safe and effective treatment for HCC. It will benefit the efficacy of RFA therapy if those risk factors are considered during the clinical practice.
|
|---|---|
| Authors | Biwei Yang, Jinghuai Zou, Jinglin Xia, Zhenggang Ren, Yuhong Gan, Yanhong Wang, Boheng Zhang, Ninglin Ge, Diane Wang, Yi Chen, Rongxin Chen, Lixin Li, Shenglong Ye, Xiangdong Wang |
| Journal | European journal of radiology (Eur J Radiol) Vol. 79 Issue 2 Pg. 196-200 (Aug 2011) ISSN: 1872-7727 [Electronic] Ireland |
| PMID | 20303686 (Publication Type: Journal Article) |
| Copyright | Copyright © 2010 Elsevier Ireland Ltd. All rights reserved. |
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!